Omixon is a global biotechnology company that commercializes disruptive innovations specializing in targeted applications for Next Generation Sequencing (NGS). The Omixon Holotype HLA™ product combines a targeted HLA Assay and the Omixon HLA Twin™ software to deliver the most accurate high-resolution HLA genotyping available. Omixon maintains an active grant-funded research program and assists scientists and clinicians to analyze the most challenging genomic regions including HLA, KIR and ABO.
Authors: Szilveszter Juhos, György Horváth, Krisztina Rigó, Jamie Duke, Deborah Ferriola, Tim Hague, Dimitri Monos Introduction: IMGT/HLA 3.19.0 contains 12705 sequences, 11464 of them are partial Sanger can cover only some part of the important exons, NGS can do a whole-gene …more
EFI 2015, Success for All We had a tremendous experience last week in the amazingly picturesque city of Geneva Switzerland – the backdrop for EFI 2015, facilitated by Prof. Jean-Marie Tiercy and Dr. Jean Villard and their team of professional …more